These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28901493)

  • 1. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
    Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
    Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
    Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
    Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
    Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
    Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
    [No Abstract]   [Full Text] [Related]  

  • 5. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
    Chiu LY; Ko JL; Lee YJ; Yang TY; Tee YT; Sheu GT
    Toxicol Lett; 2010 Feb; 192(3):408-18. PubMed ID: 19944135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
    Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
    Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
    Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
    Chen X; Yang Y; Katz SI
    PLoS One; 2018; 13(8):e0202384. PubMed ID: 30142195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
    Yoon JY; Park CK; Choi YD; Oh IJ; Kim YC
    Thorac Cancer; 2019 Apr; 10(4):942-949. PubMed ID: 30864258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
    Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
    Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
    Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
    J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
    Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
    Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.